US · BLCO
Bausch + Lomb Corporation
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Vaughan, ON L4K 4B4
- Website
- bausch.com
Price · as of 2025-12-31
$16.31
Market cap 6.48B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $27.83 | +70.63% |
| Intrinsic Value(DCF) | $7.36 | -54.87% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $14.69 | $0.05 | |||
| 2021 | $16.15 | $9.40 | |||
| 2022 | $15.90 | $30.09 | $0.15 | $7.30 | $0.14 |
| 2023 | $16.33 | $29.60 | $0.00 | $2.78 | $0.00 |
| 2024 | $16.10 | $62.52 | $0.00 | $1.04 | $0.00 |
| 2025 | $18.41 | $27.83 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Bausch + Lomb Corporation's (BLCO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $27.83
- Current price
- $16.31
- AI upside
- +70.63%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$7.36
-54.87% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BLCO | Bausch + Lomb Corporation | $16.31 | 6.48B | +71% | -55% | — | — | -18.50 | 1.01 | 1.28 | 20.11 | -138.78 | -4.09 | 58.71% | 3.12% | -7.06% | -5.45% | 1.41% | -2.56% | 0.83 | 0.37 | 1.55 | 0.84 | 8.72 | 1333.00% | 647.00% | 1186.00% | -1.01% | 0.15 | -0.59% | 0.00% | 0.00% | 0.00% | 72.33 | -174.25 | 2.25 | 0.92 |
| ACLX | Arcellx, Inc. | $113.79 | 6.58B | -42% | — | — | — | -28.05 | — | — | -31.38 | -27.10 | — | 0.00% | — | — | -100.68% | 644.58% | -39.69% | — | -10.45 | — | — | 0.00 | 10350.00% | -10000.00% | 11938.00% | -3.31% | — | 541.60% | 0.00% | 0.00% | 0.02% | -25.37 | -30.21 | — | — |
| ARWR | Arrowhead Pharmaceuticals… | $63.27 | 8.86B | +5,558% | +96,147% | -95% | — | 272.90 | 17.63 | 9.91 | 46.50 | — | 17.90 | 97.12% | 11.86% | -0.20% | 9.24% | 42.67% | 2.39% | 0.79 | 1.10 | 4.86 | 4.74 | 0.85 | -9976.00% | 2325815.00% | -12596.00% | 1.91% | 0.92 | 116.49% | 0.00% | 0.00% | 7.42% | 77.94 | 48.86 | 9.24 | 5.43 |
| CRSP | CRISPR Therapeutics AG | $60.14 | 5.77B | -40% | -46% | — | +738% | -9.40 | 2.84 | 1556.91 | -7.08 | -19.15 | 2.84 | -6537.01% | -16191.40% | -16569.77% | -30.18% | -191.73% | -25.81% | 0.21 | — | 13.32 | 13.25 | -0.07 | 4908.00% | -8997.00% | 13911.00% | -6.33% | -2.31 | -116.70% | 0.00% | 0.00% | 0.00% | -6.83 | -11.23 | 1106.51 | 8.49 |
| GKOS | Glaukos Corporation | $120.40 | 6.99B | -42% | +3% | — | — | -51.83 | 10.56 | 13.65 | -45.16 | -281.48 | 15.48 | 55.72% | -39.33% | -36.99% | -18.78% | -36.24% | -14.31% | 0.21 | -43.06 | 4.69 | 3.82 | -0.32 | 1841.00% | 3233.00% | -2013.00% | -0.78% | -0.46 | -10.09% | 0.00% | 0.00% | 0.00% | -34.01 | -125.68 | 13.38 | 16.38 |
| MMSI | Merit Medical Systems, In… | $77.18 | 4.58B | +4% | -60% | -62% | -45% | 35.22 | 2.86 | 2.99 | 14.98 | 715.00 | 8.38 | 48.70% | 12.19% | 8.48% | 8.67% | 7.25% | 5.03% | 0.57 | 6.98 | 4.34 | 2.80 | 1.35 | 493.00% | 1175.00% | 1800.00% | 4.77% | 1.24 | 11.26% | 0.00% | 0.00% | 0.00% | 26.93 | 23.07 | 3.28 | 4.04 |
| OSCR | Oscar Health, Inc. | $13.64 | 3.54B | +238% | +3,520% | — | — | -8.28 | 3.75 | 0.31 | -0.28 | — | 3.75 | 14.38% | -3.39% | -3.79% | -44.49% | 23.17% | -7.93% | 0.44 | -22.52 | 0.95 | 0.91 | 5.99 | -186594.00% | 2750.00% | 1138.00% | 28.86% | 0.23 | -61.87% | 0.00% | 0.00% | 30.44% | -0.27 | 0.10 | 0.01 | 1.28 |
| PCVX | Vaxcyte, Inc. | $61.74 | 8.86B | — | — | — | — | -11.00 | 3.14 | — | -9.58 | -22.85 | 3.14 | 0.00% | — | — | -25.59% | -61.93% | -23.38% | 0.09 | — | 7.91 | 7.81 | -0.07 | 4816.00% | — | 4089.00% | -7.93% | -3.19 | -44.87% | 0.00% | 0.00% | 0.00% | -7.69 | -10.61 | — | 12.61 |
| PTCT | PTC Therapeutics, Inc. | $68.19 | 5.47B | +340% | +35% | -42% | +1,382% | 7.73 | -25.71 | 3.05 | 4.31 | — | -7.80 | 95.85% | 49.49% | 39.44% | -104.75% | -117.79% | 29.58% | -2.40 | 5.63 | 2.35 | 2.20 | -0.55 | -26448.00% | 11451.00% | -48603.00% | 13.31% | 0.73 | -98.57% | 0.00% | 0.00% | 41.37% | 4.47 | 5.45 | 2.21 | 1.69 |
| TFX | Teleflex Incorporated | $122.06 | 5.39B | -20% | -55% | — | +315% | -6.06 | 1.76 | 2.75 | 17.49 | — | -7.79 | 56.24% | 2.94% | -45.45% | -24.47% | 1.35% | -12.90% | 0.06 | 0.58 | 2.54 | 0.95 | -0.64 | -146824.00% | -3461.00% | -9972.00% | 0.03% | 0.13 | 0.03% | 1.10% | -6.70% | 36.82% | 90.40 | 3659.08 | 2.66 | 2.01 |
| TGTX | TG Therapeutics, Inc. | $30.09 | 4.78B | +200% | +4,085% | -34% | +845% | 9.49 | 6.55 | 6.88 | 33.25 | 0.54 | 6.55 | 83.62% | 20.01% | 72.56% | 102.75% | 36.31% | 54.50% | 0.01 | 4.61 | 4.10 | 2.91 | -0.58 | 174667.00% | 8732.00% | -3840.00% | -0.59% | -0.16 | -7.36% | 0.00% | 0.00% | 5.57% | 33.32 | -164.45 | 6.67 | 6.21 |
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
- CEO
- Brenton L. Saunders
- Employees
- 13.5K
- Beta
- 0.61
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($7.36 ÷ $16.31) − 1 = -54.87% (DCF, example).